Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380624 · ClinicalTrials.gov registry record · Phase 4
Tear Lipid Layer Thickness With Emollient Eye Drops
A Phase 4 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT03380624 is a Phase 4 study that has completed, run by Ohio State University. The registered enrollment target is 21 participants.
The verdict
NCT03380624, a Phase 4 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
Crossover comparison of lipid layer thickness with two artificial tear formulations
Interventions
- DRUG Refresh Optive MEGA-3
- DRUG Refresh Optive
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03380624
The ClinicalTrials.gov registry entry for NCT03380624 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Refresh Optive MEGA-3 is the first listed.
NCT03380624 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03380624 about?
NCT03380624 is a clinical study titled "Tear Lipid Layer Thickness With Emollient Eye Drops". Crossover comparison of lipid layer thickness with two artificial tear formulations
What is the current status of trial NCT03380624?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2017-03-01. Estimated completion is 2018-06-30.
What interventions are being tested in trial NCT03380624?
The interventions under investigation include: Refresh Optive MEGA-3 (DRUG), Refresh Optive (DRUG).
Who is sponsoring clinical trial NCT03380624?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.